In the era of more aggressive immunosuppressive regimens and antiviral prophylaxis,
ganciclovir-resistant cytomegalovirus (CMV) has been recognized as an important clinical …

BACKGROUND: Since ganciclovir-resistant cytomegalovirus (CMV) disease was initially
described in a patient with acquired immunodeficiency syndrome (AIDS) in 1986, the …

Clinical consequences of ganciclovir resistant cytomegalovirus (CMV) infections were
studied during 2 large prophylactic trials consisting of 100 days of valganciclovir or …

Background. Cytomegalovirus (CMV) resistance to ganciclovir has become increasingly
common in acquired immu; nodeficiency syndrome patients but has only rarely been …

Abstract Ganciclovir-resistant (GanR) cytomegalovirus (CMV) is an emerging clinical
problem in organ transplant recipients, particularly recipients of kidney and pancreas and …

JM Iwasenko, GM Scott, Z. Naing, AR Glanville, WD Rawlinson. Diversity of antiviral‐
resistant human cytomegalovirus in heart and lung transplant recipients. Transpl Infect Dis …

The resistance of cytomegalovirus (CMV) to ganciclovir is a factor in therapeutic failure and
disease progression. The clinical significance of such resistance in solid-organ …

Despite advances in the prophylaxis and acute treatment of cytomegalovirus (CMV), it
remains an important pathogen affecting the short-and long-term clinical outcome of solid …

BACKGROUND: Cytomegalovirus (CMV) disease is a major cause of morbidity and mortality
after lung transplantation despite ganciclovir prophylaxis. The emergence of ganciclovir …

Background. Ganciclovir‐resistant (GCV‐R) cytomegalovirus (CMV) is now being reported
with increasing frequency in solid organ transplant recipients. Objective. To describe the …